Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2024-02-01 Regulatory Filings
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the loss of share certificates and the consequent stop transfer of shares until duplicate certificates are issued. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 39(3), which pertains to share transfer restrictions due to lost certificates. The content is an announcement of a specific event related to share certificates, not a financial report, management discussion, or any other detailed report type. The document length is short (2406 characters) and it is a notification to the exchanges rather than a report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice (2174 characters) informing about the availability of the audio recording of the Q3 & 9MFY24 Earnings Conference Call on the company's website. It references the SEBI Listing Obligations and Disclosure Requirements Regulations, indicating a regulatory disclosure. The document does not contain the transcript or detailed financial data but only announces the availability of the earnings call recording. According to the 'MENU VS MEAL' rule, such a short announcement that points to a report or recording elsewhere should be classified as a Regulatory Filing (RNS) rather than a Call Transcript (CT) or Earnings Release (ER).
2024-01-31 English
Shareholders meeting
Regulatory Filings
2024-01-30 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) dated 30.01.2024 from ZIM Laboratories Limited. It states that it is enclosing copies of newspaper publications regarding the financial results for the quarter and nine months ended 31 December 2023. The letter references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of financial results through newspaper publication. The document itself is a notification of the publication of financial results, not the financial results report itself. The actual financial results are published in newspapers and are enclosed or referenced but not contained in this document. The document length is about 15,000 characters but mostly contains the letter and some newspaper clipping images or text. There is no substantive financial data or analysis in this document itself. Therefore, according to the "Menu vs Meal" rule, this document is an announcement of the publication of financial results, not the financial report itself. Hence, the correct classification is Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not contain the full report.
2024-01-30 English
Updates
Investor Presentation Classification · 95% confidence The document is titled 'Q3 & 9MFY24 Earnings Presentation' and is addressed to stock exchanges, indicating it is a formal communication of quarterly and nine-month financial results. It contains detailed financial highlights, business updates, revenue breakdowns, and strategic outlooks for the periods Q3FY24 and 9MFY24. The content includes financial metrics such as Total Operating Income, EBITDA, PAT, and segment revenue contributions, which are typical of earnings presentations. The document is approximately 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full quarterly report with comprehensive financial statements, but rather a presentation summarizing earnings and business performance. Therefore, the document fits the category of an Investor Presentation (IP) rather than an Earnings Release (ER) or Interim Report (IR).
2024-01-29 English
Updates
Board/Management Information Classification · 95% confidence The document is an official communication from ZIM Laboratories Limited to stock exchanges (BSE and NSE) dated January 29, 2024. It announces the appointment of a Secretarial Auditor for the financial year 2023-24. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures of material events including appointments. The content includes details about the appointment, the auditor's profile, and the effective date. There are no financial statements, management discussion, or detailed financial data present. The document is an announcement of a board/management related change (appointment of an auditor), not a full report or audit report itself. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 4151 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2024-01-29 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.